Innovent and HUTCHMED Jointly Announce NDA Acceptance in Chi

Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Endometrial Cancer with Priority Review Status

Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Endometrial Cancer with Priority Review Status

streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

Rhui Zhou , Guangdong , China , Macau , United States , Suzhou , Jiangsu , Hong Kong , Michael Shi , Eli Lilly , Innovent Biologics , Adimab Incyte , Nasdaq , Md Anderson Cancer Center , China Limited , Prnewswire Innovent Biologics Inc , Thejournal Of The American Medical Association , National Reimbursement Drug List , China National Reimbursement Drug List , China National Medical Products Administration , Linkedin , New Drug Application , Senior Vice President , Chief Medical Officer , Breakthrough Therapy , Fruquintinib Approval , American Medical Association , Mismatch Repair , Global Cancer Observatory , World Fact , Practice Guidelines ,